X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Zokinvy (lonafarnib) is a first-in-class farnesyltransferase inhibitor. It is approved for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies.
Lead Product(s): Lonafarnib
Therapeutic Area: Genetic Disease Product Name: Zokinvy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: AnGes
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2024
Details:
Lonafarnib is a first-in-class, oral prenylation inhibitor which inhibits a host enzyme, blocking a critical step in HDV viral assembly. Lonafarnib has been dosed in over 450 chronically infected HDV patients across global clinical sites, including the Phase 3 D-LIVR study.
Lead Product(s): Lonafarnib
Therapeutic Area: Infections and Infectious Diseases Product Name: Zokinvy
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
The primary endpoint was a reduction in risk of clinical outcome comparing hospitalizations or emergency room visits greater than six hours after a single subcutaneous injection of peginterferon lambda,type III interferon (IFN) versus placebo through Day 28.
Lead Product(s): Peginterferon Lambda
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
Peginterferon lambda is an investigational late-stage, first-in-class, type III interferon (IFN) that stimulates immune responses that are critical for the development of host protection during viral infections and has been well-tolerated in clinical studies.
Lead Product(s): Peginterferon Lambda
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
Zokinvy® (lonafarnib), is a first-in-class disease-modifying agent that blocks the accumulation of defective progerin and progerin-like proteins which leads to cellular instability and premature aging in children and young adults with progeria.
Lead Product(s): Lonafarnib
Therapeutic Area: Genetic Disease Product Name: Zokinvy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Progeria Research Foundation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2022
Details:
Sarasar (lonafarnib) is a well-characterized, first-in-class, inhibitor of farnesyl-transferase, an enzyme involved in modification of proteins through a process called prenylation. HDV uses this host cell process inside liver cells to complete a key step in its life cycle.
Lead Product(s): Lonafarnib,Peginterferon Lambda,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Sarasar
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
Details:
Results of avexitide (Exendin 9-39) in patients with PBH and hyperinsulinemic hypoglycemia (HH) after other gastrointestinal surgeries, demonstrating statistically significant reductions in hypoglycemia and meeting the primary and secondary endpoints of the study.
Lead Product(s): Avexitide
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2022
Details:
Zokinvy (lonafarnib), is a well-characterized, first-in-class, orally active inhibitor of farnesyl transferase, an enzyme involved in modification of proteins through a process called prenylation.
Lead Product(s): Lonafarnib,Peginterferon Lambda,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Zokinvy
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
Zokinvy (lonafarnib) is a first-in-class disease-modifying agent that has demonstrated a statistically significant survival benefit in children and young adults with HGPS.
Lead Product(s): Lonafarnib
Therapeutic Area: Genetic Disease Product Name: Zokinvy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2022
Details:
Under the terms of the agreement, AnGes is responsible for obtaining and maintaining regulatory approval for Zokinvy (lonafarnib) in Japan and will be the exclusive partner for distribution and commercialization.
Lead Product(s): Lonafarnib
Therapeutic Area: Genetic Disease Product Name: Zokinvy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: AnGes
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
